2017-03-16,Protalix BioTherapeutics Reports 2016 Full Year Results And Provides Corporate Update
2017-03-09,Protalix BioTherapeutics To Hold Full-Year 2016 Financial Results And Corporate Update Conference Call On March 16, 2017
2017-02-17,Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
2017-02-14,Protalix BioTherapeutics Announces Record Date For The 2017 Annual Meeting Of Stockholders
2017-02-13,Protalix BioTherapeutics To Participate In The 13th Annual WORLDSymposium™ 2017
2017-01-09,Protalix BioTherapeutics Provides Review Of 2016 And Strategic Outlook For 2017
2017-01-03,Protalix BioTherapeutics Announces Positive Interim Results From Phase II Clinical Trial Of Alidornase Alfa (AIR DNase™) For The Treatment Of Cystic Fibrosis
2016-12-27,Protalix BioTherapeutics Receives Confirmation Of Order For Over $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil
2016-12-22,Protalix BioTherapeutics Announces Last Patient Enrolled In The AIR DNase™ Phase II Clinical Trial For Cystic Fibrosis
2016-12-14,Protalix BioTherapeutics Receives Letter Detailing Intended Purchases Of Approximately $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil
2016-12-01,Protalix BioTherapeutics Announces Investor Call
2016-12-01,Protalix BioTherapeutics Announces Private Note Exchanges And Private Placement Of Secured Convertible Notes Due 2021
2016-11-30,Protalix BioTherapeutics Enrolls First Patient In Phase II Clinical Trial Of OPRX-106 For The Treatment Of Ulcerative Colitis
2016-11-22,Alfataliglicerase Approved For Pediatric Indications In Brazil For The Treatment Of Gaucher Disease In Children Four Years And Older
2016-11-09,Protalix BioTherapeutics Provides Update And Reports 2016 Third Quarter Results
2016-10-25,Protalix BioTherapeutics Doses First Patient In Global Phase III Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease
2016-09-07,Protalix BioTherapeutics Announces Presentation Of Results From The Phase I/II Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease At The Society For The Study Of Inborn Errors Of Metabolism
2016-08-10,Protalix BioTherapeutics Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease
2016-08-08,Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results
2016-07-07,Protalix BioTherapeutics Announces First Patient Dosed In The AIR DNase™ Phase II Clinical Trial For Cystic Fibrosis
2016-07-04,IIROC Trading Resumption - PLX
2016-06-06,Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial Of Fabry Disease To Support United States And European Filings
2016-06-02,Protalix BioTherapeutics To Present At The Jefferies 2016 Global Healthcare Conference
2016-05-09,Protalix BioTherapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-03-08,Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results And Provides Corporate Update
2016-03-03,Protalix BioTherapeutics Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual WORLDSymposium™ 2016
2016-02-22,Protalix BioTherapeutics To Participate In The SunTrust Robinson Humphrey Orphan Drug Day And The 12th Annual WORLDSymposium™ 2016
2015-11-16,Protalix BioTherapeutics To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-of-Phase II Meeting With FDA
2015-11-09,Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results
2015-10-22,5 Stocks Under $10 Set to Soar
2015-10-21,5 Stocks Insiders Love Right Now
2015-10-19,Protalix BioTherapeutics Reports Positive Long Term Data On PRX-102 For Fabry Disease
2015-10-13,Protalix BioTherapeutics Sells Its Share In Collaboration Agreement For ELELYSO And A 6% Equity Stake In Protalix To Pfizer For A Total Of $46 Million
2015-10-05,Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF
2015-09-09,Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data On The 1mg/kg Cohort Of PRX-102 For Fabry Disease
2015-08-10,Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results
2015-08-03,Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF
2015-07-28,CollPlant Names Shomrat Shurtz Senior Director Of Business Development
2015-06-12,Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented At The 38th European Cystic Fibrosis Conference
2015-05-14,Protalix BioTherapeutics To Present At Two Upcoming Healthcare Conferences
2015-05-07,Protalix BioTherapeutics Reports First Quarter 2015 Financial Results
2015-03-12,Protalix BioTherapeutics Reports Full Year 2014 Financial Results And Provides Corporate Update
2015-02-12,Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data On PRX-102 For Fabry Disease At The WORLD Symposium
2015-02-02,Protalix BioTherapeutics Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease
2015-01-08,Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease
2015-01-05,Protalix BioTherapeutics To Present At The 2015 J.P. Morgan Healthcare Conference
2015-01-05,Protalix BioTherapeutics Announces New Strategy For Accelerated Growth
2014-10-20,5 Stocks Ready to Break Out and Soar Higher
2014-10-14,Interesting PLX Put And Call Options For May 2015
2014-09-29,Protalix BioTherapeutics Appoints Moshe Manor As President And Chief Executive Officer
2014-09-04,Protalix BioTherapeutics To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-28,Protalix Announces Conference Call To Discuss ELELYSO Pediatric Approval And Provide Updates On Additional Programs
2014-08-28,Why Protalix BioTherapeutics (PLX) Stock Is Surging Today
2014-08-28,Pfizer And Protalix BioTherapeutics Announce FDA Approval Of Pediatric Indication For ELELYSO™ (taliglucerase Alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher Disease
2014-07-24,Protalix BioTherapeutics Names Shlomo Yanai As Chairman Of The Board Of Directors
2014-06-27,Protalix Announces New Data On ELELYSO(TM) (taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
2014-06-23,Protalix BioTherapeutics Announces New Data On ELELYSO(TM) (taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
2014-06-18,Protalix BioTherapeutics Initiates Phase II Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease
2014-06-13,Protalix BioTherapeutics' President And Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year
2014-05-30,Protalix Announces ELELYSO(TM) (taliglucerase Alfa) Approved In Canada For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
2014-05-28,Protalix BioTherapeutics To Present At Two Upcoming Healthcare Conferences
2014-05-22,Protalix Announces ELELYSO(TM) (taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
2014-05-07,Protalix BioTherapeutics To Present At The Oppenheimer 15th Annual Israeli Conference And The MIXiii Israel Innovation Conference, Biomed
2014-04-25,Relative Strength Alert For Protalix BioTherapeutics
2014-04-23,Protalix Announces Data On Oral AntiTNF To Be Presented At Digestive Disease Week 2014 Meeting
2014-02-12,Protalix BioTherapeutics Announces Oral GCD Data To Be Presented At WORLD Symposium 2014
2014-02-06,Protalix BioTherapeutics' Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry Of Health Approved By The Brazilian National Institute Of Industrial Property
2014-01-23,Protalix Announces Successful Manufacturing Facility Evaluation By Health Canada
2014-01-17,2 Biotech Stocks Under $10 to Watch
2014-01-13,Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook
2014-01-07,Protalix BioTherapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2013-12-03,Protalix BioTherapeutics To Present At Oppenheimer's 24th Annual Healthcare Conference
2013-10-31,Protalix BioTherapeutics To Present At Upcoming Scientific And Medical Meetings
2013-10-14,Protalix BioTherapeutics Announces Positive Phase I Clinical Trial Results For Oral GCD In Gaucher Disease Patients
2013-09-23,Protalix BioTherapeutics Becomes Oversold (PLX)
2013-09-18,Protalix BioTherapeutics Announces Closing Of $69 Million Offering Of Convertible Notes
2013-09-12,Protalix BioTherapeutics Announces Pricing Of $60 Million Offering Of Convertible Notes
2013-09-11,Protalix BioTherapeutics Announces Proposed $60 Million Offering Of Convertible Notes
2013-06-20,Protalix BioTherapeutics Discloses Three New Compounds In Development
2013-06-19,Protalix BioTherapeutics And Brazil's Ministry Of Health Enter Into Supply And Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) In Brazil
2013-06-12,Protalix BioTherapeutics To Host Analyst Event In New York City
2013-05-31,Oversold Conditions For Protalix BioTherapeutics (PLX)
2013-05-29,Protalix BioTherapeutics To Present At Three Upcoming Healthcare Conferences
2013-05-20,PLX July Options Begin Trading
2013-05-08,Protalix BioTherapeutics To Present At The Oppenheimer 14th Annual Israeli Conference
2013-04-29,UPLYSO(TM) (alfataliglicerase) Approved In Mexico And Chile For The Treatment Of Gaucher Disease
2013-04-04,5 Stocks Under $10 Set to Soar
2013-04-02,Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112, An Orally-Administered Enzyme Treatment Of Gaucher Disease
2013-03-18,UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease
2013-03-07,Protalix BioTherapeutics Receives Approval To Initiate Phase I Study In Gaucher Patients With PRX-112, An Orally-Administered Candidate For The Treatment Of Gaucher Disease
2013-02-13,Protalix Announces New Clinical Data On ELELYSO(TM) To Be Presented At The WORLD Symposium 2013
2013-02-05,Protalix BioTherapeutics Reviewing Partnering And Other Alternatives
2013-02-05,Protalix BioTherapeutics To Present At The 15th Annual BIO CEO & Investor Conference
2013-01-31,Protalix BioTherapeutics Announces New Clinical Data On Taliglucerase Alfa To Be Presented At The WORLD Lysosomal Disease Network Symposium
2012-12-10,Protalix BioTherapeutics Announces First Patient Treated In Phase I/II Study Of Fabry Patients With PRX-102
2012-11-13,4 Plays Under $10 on the Rise
2012-09-27,Protalix BioTherapeutics Receives Marketing Authorization For Elelyso(TM) For The Treatment Of Gaucher Disease From The Israeli Ministry Of Health
2012-09-12,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2012-08-13,Protalix BioTherapeutics Receives FDA IND Clearance To Initiate A Phase I/II Study Of Fabry Disease Patients With PRX-102, A Modified Enzyme Replacement Therapy
2012-08-09,Protalix BioTherapeutics To Present At The Canaccord Genuity 32nd Annual Growth Conference
2012-07-24,4 Biotech Stocks Under $10 With Relative Strength
2012-06-22,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2012-06-21,5 Stocks Under $10 Set to Soar
2012-05-04,Friday's Top 10 Articles, Videos on TheStreet
2012-05-04,Biotech Stock Mailbag: Exelixis, Protalix, Arena
2012-05-01,Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO&#8482; (taliglucerase Alfa) For The Treatment Of Gaucher Disease
2012-05-01,Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX)
2012-04-19,8 Stocks Under $10 Moving Higher
2012-02-16,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-12-06,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-12-06,FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012
2011-12-01,Protalix Announces Successful European GMP Audit
2011-11-10,Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease
2011-10-26,Protalix BioTherapeutics To Present At Four Upcoming Conferences
2011-09-21,Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference
2011-09-13,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2011-09-12,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-09-08,Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology
2011-08-31,Protalix BioTherapeutics Inc. Stock Downgraded (PLX)
2011-08-18,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-08-17,Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date
2011-08-01,Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial
2011-07-15,Protalix BioTherapeutics Inc. Stock Upgraded (PLX)
2011-06-15,10 Stocks to Watch: DST, SunPower
2011-06-15,Protalix Announces Successful GMP Manufacturing Audit By Brazil's National Health Surveillance Agency
2011-04-07,Protalix BioTherapeutics To Present At The Tel Aviv Stock Exchange 100 Investment Conference
2011-02-25,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-02-24,Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX)
2011-02-11,Biotech Stock Mailbag: Protalix BioTherapeutics
2011-01-31,Biotech Calendar: Key Dates for February
2010-11-29,Pfizer And Protalix BioTherapeutics Announce Submission Of Taliglucerase Alfa For European Marketing Authorization For The Treatment Of Gaucher Disease
2010-09-13,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2010-05-17,14 Biotech Stocks Facing FDA Approval
2010-03-03,Protalix Announces Successful GMP Manufacturing Audit By Israel's Ministry Of Health
2009-12-01,Business Highlights
2009-12-01,Movers Roundup: Bed Bath & Beyond
2009-12-01,Smartphone Stocks, Under $10s and a Poland ETF
2009-12-01,Protalix Shares Fall Following Pfizer Deal
2009-12-01,Pfizer Inks Deal For New Drugmaking Technology
2009-12-01,Protalix-Pfizer Tag Team Against Genzyme: BioBuzz
2009-12-01,Pfizer Signs Development Deal With Protalix
2009-11-17,Genzyme's Termeer: Worst Biotech CEO of '09
2009-10-15,Protalix Says Gaucher Drug Met Goals In Trial
2009-09-08,Protalix's PrGCD Gets Orphan Drug Status From FDA
2009-08-31,Cell Therapeutics' Pixantrone: Priority Review or Not?
2009-08-25,Protalix Drug Will Get Faster Review From FDA
2009-08-17,Ahead Of The Bell: Gaucher Disease Treatments
2009-08-17,Protalix's Gaucher Drug Gets Early Approval
2009-08-03,Shire to Take on Genzyme With Gaucher Drug
2007-12-05,Wednesday's Health Winners & Losers
2007-10-25,Thursday's Health Winners & Losers
2007-07-27,Inverse Funds Clean Up in Market Rout
2007-06-20,Wednesday's Health Winners & Losers
2004-03-02,Plains Resources' Pipeline Sparks a Bidding War
2004-02-26,Readers React Regarding Drugs and Gas
2017-03-16,Protalix BioTherapeutics Reports 2016 Full Year Results And Provides Corporate Update
2017-03-09,Protalix BioTherapeutics To Hold Full-Year 2016 Financial Results And Corporate Update Conference Call On March 16, 2017
2017-02-17,Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
2017-02-14,Protalix BioTherapeutics Announces Record Date For The 2017 Annual Meeting Of Stockholders
2017-02-13,Protalix BioTherapeutics To Participate In The 13th Annual WORLDSymposium™ 2017
2017-01-09,Protalix BioTherapeutics Provides Review Of 2016 And Strategic Outlook For 2017
2017-01-03,Protalix BioTherapeutics Announces Positive Interim Results From Phase II Clinical Trial Of Alidornase Alfa (AIR DNase™) For The Treatment Of Cystic Fibrosis
2016-12-27,Protalix BioTherapeutics Receives Confirmation Of Order For Over $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil
2016-12-22,Protalix BioTherapeutics Announces Last Patient Enrolled In The AIR DNase™ Phase II Clinical Trial For Cystic Fibrosis
2016-12-14,Protalix BioTherapeutics Receives Letter Detailing Intended Purchases Of Approximately $24 Million Of Alfataliglicerase To Treat Gaucher Patients In Brazil
2016-12-01,Protalix BioTherapeutics Announces Investor Call
2016-12-01,Protalix BioTherapeutics Announces Private Note Exchanges And Private Placement Of Secured Convertible Notes Due 2021
2016-11-30,Protalix BioTherapeutics Enrolls First Patient In Phase II Clinical Trial Of OPRX-106 For The Treatment Of Ulcerative Colitis
2016-11-22,Alfataliglicerase Approved For Pediatric Indications In Brazil For The Treatment Of Gaucher Disease In Children Four Years And Older
2016-11-09,Protalix BioTherapeutics Provides Update And Reports 2016 Third Quarter Results
2016-10-25,Protalix BioTherapeutics Doses First Patient In Global Phase III Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease
2016-09-07,Protalix BioTherapeutics Announces Presentation Of Results From The Phase I/II Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease At The Society For The Study Of Inborn Errors Of Metabolism
2016-08-10,Protalix BioTherapeutics Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease
2016-08-08,Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results
2016-07-07,Protalix BioTherapeutics Announces First Patient Dosed In The AIR DNase™ Phase II Clinical Trial For Cystic Fibrosis
2016-07-04,IIROC Trading Resumption - PLX
2016-06-06,Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial Of Fabry Disease To Support United States And European Filings
2016-06-02,Protalix BioTherapeutics To Present At The Jefferies 2016 Global Healthcare Conference
2016-05-09,Protalix BioTherapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-03-08,Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results And Provides Corporate Update
2016-03-03,Protalix BioTherapeutics Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual WORLDSymposium™ 2016
2016-02-22,Protalix BioTherapeutics To Participate In The SunTrust Robinson Humphrey Orphan Drug Day And The 12th Annual WORLDSymposium™ 2016
2015-11-16,Protalix BioTherapeutics To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-of-Phase II Meeting With FDA
2015-11-09,Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results
2015-10-22,5 Stocks Under $10 Set to Soar
2015-10-21,5 Stocks Insiders Love Right Now
2015-10-19,Protalix BioTherapeutics Reports Positive Long Term Data On PRX-102 For Fabry Disease
2015-10-13,Protalix BioTherapeutics Sells Its Share In Collaboration Agreement For ELELYSO And A 6% Equity Stake In Protalix To Pfizer For A Total Of $46 Million
2015-10-05,Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF
2015-09-09,Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data On The 1mg/kg Cohort Of PRX-102 For Fabry Disease
2015-08-10,Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results
2015-08-03,Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF
2015-07-28,CollPlant Names Shomrat Shurtz Senior Director Of Business Development
2015-06-12,Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented At The 38th European Cystic Fibrosis Conference
2015-05-14,Protalix BioTherapeutics To Present At Two Upcoming Healthcare Conferences
2015-05-07,Protalix BioTherapeutics Reports First Quarter 2015 Financial Results
2015-03-12,Protalix BioTherapeutics Reports Full Year 2014 Financial Results And Provides Corporate Update
2015-02-12,Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data On PRX-102 For Fabry Disease At The WORLD Symposium
2015-02-02,Protalix BioTherapeutics Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease
2015-01-08,Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease
2015-01-05,Protalix BioTherapeutics To Present At The 2015 J.P. Morgan Healthcare Conference
2015-01-05,Protalix BioTherapeutics Announces New Strategy For Accelerated Growth
2014-10-20,5 Stocks Ready to Break Out and Soar Higher
2014-10-14,Interesting PLX Put And Call Options For May 2015
2014-09-29,Protalix BioTherapeutics Appoints Moshe Manor As President And Chief Executive Officer
2014-09-04,Protalix BioTherapeutics To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-28,Protalix Announces Conference Call To Discuss ELELYSO Pediatric Approval And Provide Updates On Additional Programs
2014-08-28,Why Protalix BioTherapeutics (PLX) Stock Is Surging Today
2014-08-28,Pfizer And Protalix BioTherapeutics Announce FDA Approval Of Pediatric Indication For ELELYSO™ (taliglucerase Alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher Disease
2014-07-24,Protalix BioTherapeutics Names Shlomo Yanai As Chairman Of The Board Of Directors
2014-06-27,Protalix Announces New Data On ELELYSO(TM) (taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
2014-06-23,Protalix BioTherapeutics Announces New Data On ELELYSO(TM) (taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting
2014-06-18,Protalix BioTherapeutics Initiates Phase II Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease
2014-06-13,Protalix BioTherapeutics' President And Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year
2014-05-30,Protalix Announces ELELYSO(TM) (taliglucerase Alfa) Approved In Canada For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
2014-05-28,Protalix BioTherapeutics To Present At Two Upcoming Healthcare Conferences
2014-05-22,Protalix Announces ELELYSO(TM) (taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
2014-05-07,Protalix BioTherapeutics To Present At The Oppenheimer 15th Annual Israeli Conference And The MIXiii Israel Innovation Conference, Biomed
2014-04-25,Relative Strength Alert For Protalix BioTherapeutics
2014-04-23,Protalix Announces Data On Oral AntiTNF To Be Presented At Digestive Disease Week 2014 Meeting
2014-02-12,Protalix BioTherapeutics Announces Oral GCD Data To Be Presented At WORLD Symposium 2014
2014-02-06,Protalix BioTherapeutics' Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry Of Health Approved By The Brazilian National Institute Of Industrial Property
2014-01-23,Protalix Announces Successful Manufacturing Facility Evaluation By Health Canada
2014-01-17,2 Biotech Stocks Under $10 to Watch
2014-01-13,Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook
2014-01-07,Protalix BioTherapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2013-12-03,Protalix BioTherapeutics To Present At Oppenheimer's 24th Annual Healthcare Conference
2013-10-31,Protalix BioTherapeutics To Present At Upcoming Scientific And Medical Meetings
2013-10-14,Protalix BioTherapeutics Announces Positive Phase I Clinical Trial Results For Oral GCD In Gaucher Disease Patients
2013-09-23,Protalix BioTherapeutics Becomes Oversold (PLX)
2013-09-18,Protalix BioTherapeutics Announces Closing Of $69 Million Offering Of Convertible Notes
2013-09-12,Protalix BioTherapeutics Announces Pricing Of $60 Million Offering Of Convertible Notes
2013-09-11,Protalix BioTherapeutics Announces Proposed $60 Million Offering Of Convertible Notes
2013-06-20,Protalix BioTherapeutics Discloses Three New Compounds In Development
2013-06-19,Protalix BioTherapeutics And Brazil's Ministry Of Health Enter Into Supply And Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) In Brazil
2013-06-12,Protalix BioTherapeutics To Host Analyst Event In New York City
2013-05-31,Oversold Conditions For Protalix BioTherapeutics (PLX)
2013-05-29,Protalix BioTherapeutics To Present At Three Upcoming Healthcare Conferences
2013-05-20,PLX July Options Begin Trading
2013-05-08,Protalix BioTherapeutics To Present At The Oppenheimer 14th Annual Israeli Conference
2013-04-29,UPLYSO(TM) (alfataliglicerase) Approved In Mexico And Chile For The Treatment Of Gaucher Disease
2013-04-04,5 Stocks Under $10 Set to Soar
2013-04-02,Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112, An Orally-Administered Enzyme Treatment Of Gaucher Disease
2013-03-18,UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease
2013-03-07,Protalix BioTherapeutics Receives Approval To Initiate Phase I Study In Gaucher Patients With PRX-112, An Orally-Administered Candidate For The Treatment Of Gaucher Disease
2013-02-13,Protalix Announces New Clinical Data On ELELYSO(TM) To Be Presented At The WORLD Symposium 2013
2013-02-05,Protalix BioTherapeutics Reviewing Partnering And Other Alternatives
2013-02-05,Protalix BioTherapeutics To Present At The 15th Annual BIO CEO & Investor Conference
2013-01-31,Protalix BioTherapeutics Announces New Clinical Data On Taliglucerase Alfa To Be Presented At The WORLD Lysosomal Disease Network Symposium
2012-12-10,Protalix BioTherapeutics Announces First Patient Treated In Phase I/II Study Of Fabry Patients With PRX-102
2012-11-13,4 Plays Under $10 on the Rise
2012-09-27,Protalix BioTherapeutics Receives Marketing Authorization For Elelyso(TM) For The Treatment Of Gaucher Disease From The Israeli Ministry Of Health
2012-09-12,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2012-08-13,Protalix BioTherapeutics Receives FDA IND Clearance To Initiate A Phase I/II Study Of Fabry Disease Patients With PRX-102, A Modified Enzyme Replacement Therapy
2012-08-09,Protalix BioTherapeutics To Present At The Canaccord Genuity 32nd Annual Growth Conference
2012-07-24,4 Biotech Stocks Under $10 With Relative Strength
2012-06-22,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2012-06-21,5 Stocks Under $10 Set to Soar
2012-05-04,Friday's Top 10 Articles, Videos on TheStreet
2012-05-04,Biotech Stock Mailbag: Exelixis, Protalix, Arena
2012-05-01,Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO&#8482; (taliglucerase Alfa) For The Treatment Of Gaucher Disease
2012-05-01,Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX)
2012-04-19,8 Stocks Under $10 Moving Higher
2012-02-16,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-12-06,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-12-06,FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012
2011-12-01,Protalix Announces Successful European GMP Audit
2011-11-10,Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease
2011-10-26,Protalix BioTherapeutics To Present At Four Upcoming Conferences
2011-09-21,Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference
2011-09-13,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2011-09-12,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-09-08,Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology
2011-08-31,Protalix BioTherapeutics Inc. Stock Downgraded (PLX)
2011-08-18,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-08-17,Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date
2011-08-01,Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial
2011-07-15,Protalix BioTherapeutics Inc. Stock Upgraded (PLX)
2011-06-15,10 Stocks to Watch: DST, SunPower
2011-06-15,Protalix Announces Successful GMP Manufacturing Audit By Brazil's National Health Surveillance Agency
2011-04-07,Protalix BioTherapeutics To Present At The Tel Aviv Stock Exchange 100 Investment Conference
2011-02-25,Protalix BioTherapeutics Stock Gaps Down On Today's Open (PLX)
2011-02-24,Protalix BioTherapeutics Stock Falls On Unusually High Volume (PLX)
2011-02-11,Biotech Stock Mailbag: Protalix BioTherapeutics
2011-01-31,Biotech Calendar: Key Dates for February
2010-11-29,Pfizer And Protalix BioTherapeutics Announce Submission Of Taliglucerase Alfa For European Marketing Authorization For The Treatment Of Gaucher Disease
2010-09-13,Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference
2010-05-17,14 Biotech Stocks Facing FDA Approval
2010-03-03,Protalix Announces Successful GMP Manufacturing Audit By Israel's Ministry Of Health
2009-12-01,Business Highlights
2009-12-01,Movers Roundup: Bed Bath & Beyond
2009-12-01,Smartphone Stocks, Under $10s and a Poland ETF
2009-12-01,Protalix Shares Fall Following Pfizer Deal
2009-12-01,Pfizer Inks Deal For New Drugmaking Technology
2009-12-01,Protalix-Pfizer Tag Team Against Genzyme: BioBuzz
2009-12-01,Pfizer Signs Development Deal With Protalix
2009-11-17,Genzyme's Termeer: Worst Biotech CEO of '09
2009-10-15,Protalix Says Gaucher Drug Met Goals In Trial
2009-09-08,Protalix's PrGCD Gets Orphan Drug Status From FDA
2009-08-31,Cell Therapeutics' Pixantrone: Priority Review or Not?
2009-08-25,Protalix Drug Will Get Faster Review From FDA
2009-08-17,Ahead Of The Bell: Gaucher Disease Treatments
2009-08-17,Protalix's Gaucher Drug Gets Early Approval
2009-08-03,Shire to Take on Genzyme With Gaucher Drug
2007-12-05,Wednesday's Health Winners & Losers
2007-10-25,Thursday's Health Winners & Losers
2007-07-27,Inverse Funds Clean Up in Market Rout
2007-06-20,Wednesday's Health Winners & Losers
2004-03-02,Plains Resources' Pipeline Sparks a Bidding War
2004-02-26,Readers React Regarding Drugs and Gas
